Solid Biosciences LLC

Solid Biosciences has dosed the first patient in its Phase 3 IMPACT DUCHENNE trial of gene therapy SGT-003 for Duchenne muscular dystrophy, while continuing discussions with the FDA on a potential accelerated approval pathway. Interim Phase 1/2 results reported in March showed strong microdystrophin expression and improved muscle health in 40 treated participants, with an encouraging safety profile. The company also received a positive opinion from the European Medicines Agency on its Pediatric Investigation Plan for SGT-003 and was one of only three companies to receive the UK's Innovation Passport under the Innovative Licensing and Access Pathway. Solid's other clinical-stage gene therapies include SGT-212 for Friedreich's Ataxia, with initial Phase 1b data expected by year-end 2026, and SGT-501 for catecholaminergic polymorphic ventricular tachycardia, where the first participant is anticipated to be dosed in the second half of 2026. As of March 31, 2026, the company held $380.7 million in cash, cash equivalents, and available-for-sale securities, providing an operational runway into the first half of 2028.